Edition:
India

Corbus Pharmaceuticals Holdings Inc (CRBP.OQ)

CRBP.OQ on NASDAQ Stock Exchange Global Market

6.48USD
9:36pm IST
Change (% chg)

$-0.67 (-9.37%)
Prev Close
$7.15
Open
$7.23
Day's High
$7.23
Day's Low
$6.36
Volume
405,819
Avg. Vol
395,353
52-wk High
$8.77
52-wk Low
$3.30

Latest Key Developments (Source: Significant Developments)

Corbus Pharmaceuticals Reports Q1 2019 Results
Thursday, 9 May 2019 

May 9 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS REPORTS 2019 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATES.Q1 LOSS PER SHARE $0.43.Q1 EARNINGS PER SHARE ESTIMATE $-0.27 -- REFINITIV IBES DATA.QTRLY REVENUE FROM AWARDS $1.9 MILLION VERSUS $950,442.Q1 REVENUE VIEW $1.5 MILLION -- REFINITIV IBES DATA.  Full Article

Corbus Pharma Announces Change Of Primary Endpoint In Ongoing Phase 3 Study In Systemic Sclerosis
Thursday, 18 Apr 2019 

April 18 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS ANNOUNCES CHANGE OF PRIMARY ENDPOINT IN ONGOING RESOLVE-1 PHASE 3 STUDY IN SYSTEMIC SCLEROSIS IN U.S. TO ACR CRISS FROM MRSS FOLLOWING MEETING WITH FDA.CORBUS PHARMACEUTICALS HOLDINGS INC - PHASE 3 PRIMARY ENDPOINT WILL NOW BE ALIGNED WITH THAT OF PREVIOUS PHASE 2 STUDY.CORBUS PHARMACEUTICALS HOLDINGS INC - PHASE 3 PRIMARY ENDPOINT WILL NOW BE ALIGNED WITH THAT OF PREVIOUS PHASE 2 STUDY.CORBUS PHARMACEUTICALS HOLDINGS INC - CHANGE IN MRSS WILL BECOME SECONDARY ENDPOINT.CORBUS PHARMACEUTICALS HOLDINGS INC - NO CHANGES TO CONDUCT OR SIZE OF PHASE 3 STUDY.CORBUS PHARMACEUTICALS HOLDINGS INC - REMAINS ON TRACK TO COMPLETE RESOLVE-1 STUDY IN FIRST HALF OF 2020.  Full Article

Corbus Pharmaceuticals Holdings Q4 Loss Per Share $0.30
Tuesday, 12 Mar 2019 

Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATES.Q4 LOSS PER SHARE $0.30.Q4 EARNINGS PER SHARE ESTIMATE $-0.26 -- REFINITIV IBES DATA.CONTINUED PROGRESS IN FOUR ONGOING CLINICAL STUDIES AS LENABASUM MOVES TOWARDS EXPECTED 2020 TOPLINE DATA READOUTS IN SYSTEMIC SCLEROSIS AND CYSTIC FIBROSIS STUDIES.SECOND CLINICAL CANDIDATE CRB-4001 EXPECTED TO COMMENCE CLINICAL STUDIES IN 2019.CORBUS PHARMACEUTICALS HOLDINGS - EXPECTS CURRENT CASH & CASH EQUIVALENTS TO FUND OPERATIONS INTO Q4 OF 2020, BASED ON CURRENT PLANNED EXPENDITURES.CORBUS PHARMACEUTICALS HOLDINGS - CO'S CASH AND CASH EQUIVALENTS BALANCE AT DECEMBER 31, 2018 WAS ABOUT $41.7 MILLION.  Full Article

Corbus Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Friday, 25 Jan 2019 

Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CORBUS PHARMACEUTICALS HOLDINGS - INTENDS TO USE NET PROCEEDS OF OFFERING TO FUND ITS CONTINUED DEVELOPMENT OF LENABASUM AND COMPOUNDS RECENTLY LICENSED FROM JENRIN.  Full Article

BRIEF-Corbus Pharma Reports Last Subject Visit In Phase 2B Study Of Lenabasum For Treatment Of Cystic Fibrosis

* CORBUS PHARMACEUTICALS REPORTS LAST SUBJECT VISIT IN PHASE 2B STUDY OF LENABASUM FOR TREATMENT OF CYSTIC FIBROSIS